Adoptive Transfer of Mammaglobin-A Epitope Specific CD8 T Cells Combined with a Single Low Dose of Total Body Irradiation Eradicates Breast Tumors

Nadine M. Lerret1, Magdalena Rogozinska1, Andrés Jaramillo2,3, Amanda L. Marzo1

1 Rush University Medical Center, Department of Immunology and Microbiology, Chicago, Illinois, United States of America, 2 Rush University Medical Center, Department of Pathology, Chicago, Illinois, United States of America, 3 Histocompatibility Laboratory, Gift of Hope Organ & Tissue Donor Network, Itasca, Illinois, United States of America

Abstract

Adoptive T cell therapy has proven to be beneficial in a number of tumor systems by targeting the relevant tumor antigen. The tumor antigen targeted in our model is Mammaglobin-A, expressed by approximately 80% of human breast tumors. Here we evaluated the use of adoptively transferred Mammaglobin-A specific CD8 T cells in combination with low dose irradiation to induce breast tumor rejection and prevent relapse. We show Mammaglobin-A specific CD8 T cells generated by DNA vaccination with all epitopes (Mammaglobin-A2.1, A2.2, A2.4 and A2.6) and full-length DNA in vivo resulted in heterogeneous T cell populations consisting of both effector and central memory CD8 T cell subsets. Adoptive transfer of spleen cells from all Mammaglobin-A2 immunized mice into tumor-bearing SCID/beige mice induced tumor regression but this anti-tumor response was not sustained long-term. Additionally, we demonstrate that only the adoptive transfer of Mammaglobin-A2 specific CD8 T cells in combination with a single low dose of irradiation prevents tumors from recurring. More importantly we show that this single dose of irradiation results in the down regulation of the macrophage scavenger receptor 1 on dendritic cells within the tumor and reduces lipid uptake by tumor resident dendritic cells potentially enabling the dendritic cells to present tumor antigen more efficiently and aid in tumor clearance. These data reveal the potential for adoptive transfer combined with a single low dose of total body irradiation as a suitable therapy for the treatment of established breast tumors and the prevention of tumor recurrence.

Citation: Lerret NM, Rogozinska M, Jaramillo A, Marzo AL (2012) Adoptive Transfer of Mammaglobin-A Epitope Specific CD8 T Cells Combined with a Single Low Dose of Total Body Irradiation Eradicates Breast Tumors. PLoS ONE 7(7): e41240. doi:10.1371/journal.pone.0041240

Editor: R. Lee Mosley, University of Nebraska Medical Center, United States of America

Received December 5, 2011; Accepted June 22, 2012; Published July 20, 2012

Copyright: © 2012 Lerret et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Susan G. Komen for the Cure (Grant# BCTR0600731; A.L.M. and A.J.), the Prevent Cancer Foundation (A.L.M. and A.J.), the Brian Piccolo/Covers Cancer Research Foundation (A.L.M.), and a Rush UCR grant (A.L.M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Amanda_Marzo@rush.edu

Introduction

Two major goals in tumor vaccination are to induce regression of established tumors and to generate long-lasting tumor-specific immunity capable of protecting the host from relapse. The ability to confer long-term protection in cancer has been limited largely by the inability to generate effective memory CD8 T cell responses. Memory CD8 T cells are endowed with unique properties that permit more vigorous and specific responses upon re-challenge to protect against tumor challenge. Memory CD8 T cells are long-lived cells with heightened capacity to respond to subsequent insults that have been divided into two sub-populations, central memory T cells (T~CM~) and effector memory T cells (T~EM~), based on their expression of CCR7 and CD62L [1]. Ideally DNA vaccination would induce a robust population of both memory T cell subsets with the T~EM~ acting as the initial defenders against tumor challenge and T~CM~ replenishing the pool of T~EM~. Nonetheless, DNA vaccination in the cancer setting has often failed due to the lack of T cell antigens expressed by cancer cells. More recently, Mammaglobin-A (Mam-A) has been found to be a clinically relevant breast cancer-associated antigen that is over-expressed in both human breast cancer cell lines and primary human breast tumors [2]. Mam-A expression is similar on well-differentiated, moderately differentiated, and poorly differentiated primary breast tumors [2,3]. Furthermore, this protein is frequently produced by metastatic breast cancer cells [2]. Previously, CD8 T cells generated by vaccination with full-length Mam-A DNA were able to specifically induce the regression of Mam-A+ breast cancer tumors in vivo [3,4] but their ability to provide long-term tumor specific immunity was not determined. These studies also demonstrated that CD8 T cells from HLA-A2+ breast cancer patients and vaccinated HLA-A2+ transgenic mice recognized a similar epitope profile derived from the Mam-A protein [3,4]. In this regard, HLA-A2+ transgenic mice have been previously shown to recognize similar epitopes from influenza virus, hepatitis C virus, cytomegalovirus, and leukemia-associated antigens as HLA-A2+ humans [5,6,7,8]. Four epitopes derived from Mam-A (Mam-A2.1, A2.2, A2.4, and A2.6) have been identified that are recognized by vaccinated HLA-A2+ transgenic mice [3,4]. However, whether or not these epitope-specific CD8 T cells could lead to in vivo tumor regression and prevent tumor recurrence was not determined. Thus our objective was to determine if vaccination with any of the Mam-A epitope cDNA constructs would result in a more effective and prolonged CD8
**Results**

DNA vaccination with all Mam-A epitopes generates a heterogeneous population of CD8 T cells consisting of both central and effector memory CD8 T cells

To study the effect of Mam-A DNA vaccination on the generation of long-lived effector CD8 T cells we enumerated and phenotyped the Mam-A specific CD8 T cells generated after vaccination with full-length or Mam-A epitope encoded DNA. HLA-A2+ transgenic mice were vaccinated four times with Mam-A DNA (full-length or epitopes). Five days after the last vaccination, the percent of tetramer positive of Mam-A specific CD8+CD11a+ T cells were found to be similar amongst the different Mam-A epitopes and full-length DNA vaccinations (Fig. 1a). Furthermore, when total numbers of Mam-A tetramer+ CD8+CD11a+ T cells were analyzed, Mam-A2.2, Mam-A2.4, Mam-A2.6 and full-length DNA vaccination induced similar numbers of total Mam-A specific CD8 T cells while vaccination with full-length Mam-A, Mam-A2.4 and Mam-A2.6 induced similar numbers of CD62L+CD27- Mam-A specific CD8 T cells (25,26 and 30%, respectively) whereas vaccination with Mam-A2.2 and Mam-A2.6 induced slightly more CD62L+CD27+ Mam-A specific CD8 T cells (42 and 46% respectively). Interestingly, vaccination with Mam-A2.2 DNA failed to induce the CD62L+CD27- population. In contrast, vaccination with the full-length Mam-A, Mam-A2.4, Mam-A2.1 and Mam-A2.6 induced Mam-A specific CD8 T cells with a CD62L+CD27- phenotype (17, 23, 22 and 27%, respectively). The cell surface marker CD122, defined as the β-chain of IL-2R and IL-15R, confers responsiveness to IL-15, a cytokine crucial for the maintenance of memory CD8 T cells induced through homeostatic proliferation [20]. Analysis of CD122 expression revealed that DNA vaccination with Mam-A2.4 was capable of inducing a slightly higher percentage of CD122+CD8+ T cells (24%) compared to full-length Mam-A, Mam-A2.2, Mam-A2.1 and Mam-A2.6 (16, 13, 9 and 14% respectively, Fig.S1). Additionally, CD127 (IL-7Rα) is important for development and survival of memory CD8 T cells and is highly expressed on a subset of effector CD8 T cells known as memory precursor effector cells (MPECs) that eventually become long-lived TEM [21,22,23] [24]. Mam-A2.4 DNA vaccination induced a slightly larger percentage of antigen-specific CD127+ CD8 T cells when compared to Mam-A epitopes 2.1,2.2 and 2.6 or full-length vaccination (Fig.S1). These results indicate that in our model, vaccination with all epitopes and full-length Mam-A DNA can induce effector CD8 T cells, Mam-A2.2 and Mam-A2.4 specific CD8 T cells have an increased capacity to be maintained and respond more effectively in subsequent tumor challenges as a result of their increased levels of CD122.

We subsequently evaluated the functional capacity of Mam-A specific CD8 T cells by measuring their ability to produce IFN-γ in response to a single Mam-A epitope (Mam-A2.1 A2.2, A2.4, A2.6 or a combination of all epitopes (full-length Mam-A equivalent)). Vaccination with all Mam-A epitopes induced equal amounts of IFN-γ production (Fig.S1). In contrast, vaccination with full-length Mam-A was unable to induce IFN-γ-producing cytotoxic CD8 T cells. TNF-α production was also analyzed after vaccination with full-length and Mam-A epitope DNA, there were no significant difference in TNF-α production when compared to the isotype control in any of the Mam-A tetramer+ T cells (data not shown). As most tumor-associated antigens are derived from a mutated form of self and since T-reg play a key role in maintaining self-tolerance, we analyzed whether or not vaccination with either full-length or epitope encoded Mam-A DNA induced higher numbers of T-regs (CD4+CD25+FoxP3+). While relatively similar numbers of T-regs were produced following the majority of immunization regimes, full-length Mam-A induced a slightly smaller number of T-regs (Fig.S1). Taken together, these data indicate that DNA vaccination with all epitopes and full-
Figure 1. DNA vaccination with all Mam-A epitopes generates a heterogeneous population of Mam-A2 specific CD8 T cells that are maintained at various frequencies in vivo. (A) HLA-A2\textsuperscript{+} transgenic mice vaccinated four times separated by 2-week intervals with Mam-A encoded cDNA. 5 days after the last vaccination, animals were sacrificed and spleen cells were harvested. As a negative control, spleen cells were also harvested from unvaccinated HLA-A2\textsuperscript{+} transgenic mice. Lymphocytes were stained and CD8\textsuperscript{+} CD11ahi T cells were gated on first and then the tetramer\textsuperscript{+} CD8 T cells were gated and this gate was used to determine the percent of Mam-A tetramer positive of CD8 T cells and (B) the total number of tetramer positive CD8 T cells. A representative gating scheme for all groups is shown. Only the Mam-A tetramer positive cells were collected via flow
length Mam-A DNA can induce a heterogeneous population of CD8 T cells (Fig. 1 and Fig.S1).

We next enumerated the total number of Mam-A-tetramer+ of CD8+CD11a−/− T cells from the spleen, DLN and tumor of SCID-beige tumor bearing mice 7 and 28 days after the transfer of splenocytes from Mam-A DNA vaccinated HLA-A2 transgenic mice. Mam-A2.2 and A2.4 specific CD8 T cells were maintained at a higher frequency in the spleen 7 days post transfer than either full length or the other epitopes (Fig. 1d). In contrast, in all vaccination groups, a similar number of Mam-A-tetramer+ CD8 T cells were present in the DLN 7 days post transfer (Fig. 1e). When analyzing the tumor infiltrating Mam-A specific CD8 T cells 7 days post transfer, mice that had received splenocytes from Mam-A2.2 and Mam-A2.4 vaccinated mice were found to have a larger number of Mam-A specific tetramer+ CD8 T cells compared to Mam-A2.1, Mam-A2.6 and full-length vaccinated mice (Fig. 1f). By day 28 post transfer, the total number of Mam-A2.4 specific CD8 T cells found within the spleen was significantly higher than the other Mam-A epitopes or full-length Mam-A specific CD8 T cells (Fig. 1g). However, by day 28 in the DLN, Mam-A2.4 and Mam-A2.6 specific CD8 T cells were present at significantly higher numbers than the other Mam-A epitopes (Fig. 1h).

Immunohistochemical analysis revealed that CD8 T cells from animals vaccinated with DNA encoding for all Mam-A epitopes as well as full-length Mam-A infiltrated the spleens and DLN but only CD8 T cells from Mam-A2.4 infiltrated the tumor on day 7 (Fig. 2a–2b). By day 28, infiltration of CD8 T cells was observed in the tumor from mice receiving spleen cells from all vaccination groups (Fig. 2c–2d). However, mice receiving spleen cells from Mam-A2.4 DNA vaccinated mice were observed to have the highest number of tumor infiltrating CD8 T cells on day 28 and these cells were still present at day 35 (Fig. 2c–2f). Morphometric analysis confirmed the increased presence of CD8 T cells in mice receiving spleen cells from Mam-A2.4 DNA vaccinated mice (Fig. 2).

Mam-A2 specific CD8 T cells that accumulate in the tumor earlier and maintained longer are predominantly CD27lo/CD62Llo/CD127hi

We next analyzed the phenotype and function of the Mam-A tetramer+ CD8+CD11a−/− T cells from the spleens of SCID-beige tumor bearing mice. By day 7 post transfer there were no Mam-A specific CD8 TEM (CD27lo/CD62Lhi) present in the spleens of mice that received either full-length Mam-A or any of the Mam-A epitopes (Fig. 3a). Although the percentage of Mam-A specific CD8 TEM defined as CD27lo were the same amongst the different experimental groups 7 days post transfer, analysis of the TEM subsets (defined by the expression of CD27 and CD62L) revealed that the majority of Mam-A specific CD8 T cells from mice that received splenocytes from full-length, Mam-A2.2 and Mam-A2.4 vaccinated mice 7 days prior were of the CD27lo/CD62Lhi TEM phenotype (78, 71 and 84%, respectively). On the other hand, mice that had received either Mam-A2.1 or Mam-A2.6 had fewer CD27lo/CD62Lhi CD8 T EM cells (58 and 51%, respectively) with a proportionally larger population of CD27hi/CD62Llo CD8 T EM cells. Analysis of CD122 expression revealed similar MFI levels amongst CD8 T cells from mice vaccinated with full-length Mam-A, Mam-A2.2 and Mam-A2.4 with slightly lower MFIs for CD8 T cells from mice vaccinated with Mam-A2.1 and Mam-A2.6. In contrast, CD127 expression was higher in the animals that received Mam-A2.4 compared to full-length, Mam-A2.2, Mam-A2.1 and Mam-A2.6 (428, 283, 285, 207 and 200, respectively), consistent with their ability to persist long-term. By day 28 the CD62L profiles were similar to that at day 7 (Fig. 3b). However, by this time-point more of the CD62Llo Mam-A epitope specific CD8 T cells expressed CD27 compared to day 7 (Fig. 3b). While CD122 expression on CD8 T cells was similar amongst the groups, CD8 T cells from mice vaccinated with full-length and Mam-A2.4 specific CD8 T cells expressed slightly more CD127 than CD8 T cells from mice vaccinated with the other Mam-A epitopes (MFI of 357, 251, 159, 111 and 131, respectively).

CD27lo/CD62Llo/CD127hi Mam-A2 specific CD8 T cells (Mam-A2.4) secrete more IFN-γ, TNF-α and express more Granzyme B post transfer than other Mam-A epitope specific CD8 T cells

The capacity of these Mam-A specific CD8 T cells to secrete IFN-γ, TNF-α and express Granzyme B on days 7 and 28 post transfer was analyzed (Fig. 3c–3d). Even though CD8 T cells derived from mice vaccinated with either full-length or Mam-A epitope DNA secreted similar amounts of both IFN-γ and TNF-α before transfer (Fig S1 and data not shown) 7 days after transfer, Mam-A2.4 specific CD8 T cells secreted at least 5 times more IFN-γ and at least twice as much TNF-α when compared to CD8 T cells specific for the other Mam-A epitopes or full-length Mam-A (Fig. 3c). In addition, Mam-A2.4 specific CD8 T cells also expressed at least 3 times more Granzyme B than CD8 T cells specific for the other epitopes (Fig. 3c). While similar numbers of Mam-A2.2 CD8 T cells were seen at day 7 post transfer when compared to Mam-A2.4 CD8 T cells (Fig. 1d) these Mam-A2.2 specific CD8 T cells secreted less IFN-γ, TNF-α and expressed less Granzyme B compared to Mam-A2.4 CD8 T cells (Fig. 3c). By day 28 after transfer, the Mam-A2.4 specific CD8 T cells continued to secrete significantly more IFN-γ and TNF-α compared to CD8 T cells specific for either full-length or the other Mam-A epitopes (Fig. 3d).

CD8 T cells from mice vaccinated with Mam-A2.4 DNA induce long-term tumor regression and survival in vivo when compared to CD8 T cells from mice vaccinated with full-length Mam-A DNA or other Mam-A epitope DNA but are unable to prevent recurrence of tumor

While we have shown that vaccination of HLA-A2 transgenic mice with Mam-A2.4 encoded DNA produces splenocytes that have the phenotype and functional attributes required for a successful long-lived antitumor response (Fig. 1 and Fig S1), their...
Figure 2. CD8+ T cells from Mam-A2.4 DNA vaccinated HLA-A2+ transgenic mice traffic into breast tumors at a higher frequency. Spleen (SP), draining lymph node (DLN) and tumor (TIL) sections from SCID-beige mice receiving splenocytes from HLA-A2+ transgenic mice vaccinated with cDNA encoding either full-length or Mam-A epitopes were analyzed by means of immunohistochemistry for the presence of CD8 T cells (A) 7, and (C) 28 days post transfer (magnification of 20×). Morphometric analysis was also performed (B) 7 and (D) 28 days post transfer. Results are expressed as the mean (±SEM) of 3 different experiments. (E–F) Spleen (SP), draining lymph node (DLN) and tumor (TIL) sections from SCID-beige...
mice receiving splenocytes from HLA-A2 transgenic mice vaccinated with cDNA encoding Mam-A2.4 were analyzed for the presence of CD8 T cells on days 7, 21, 28 and 35 post spleen cell transfer. Data are representative of at least 2 experiments with at least 3 mice per group/experiment.

*P < 0.05, **P < 0.01 and ***P < 0.0001.

doi:10.1371/journal.pone.0041240.g002

Figure 3. CD8 T cells from Mam-A2.4 DNA vaccinated HLA-A2 transgenic mice are significantly more cytotoxic. Tumor-bearing SCID-beige mice received spleen cells (1 × 10^7 i.p) from HLA-A2 transgenic mice that were vaccinated with cDNA encoding for either full-length or epitope-specific Mam-A. (A) Animals were sacrificed 7 or (B) 28 days later and Mam-A tetramer-specific CD11ahiCD8 T cells from the spleens were analyzed via flow cytometry for CD122, CD127, CD27, and CD62L expression. Data are representative of at least 3 experiments with 3–4 mice per group. Mam-A specific T cells were analyzed for IFN-γ, TNF-α and granzyme B production after stimulation with 40 μg/ml of the corresponding Mam-A peptides (C) 7 and (D) 28 days post adoptive transfer of Mam-A specific splenocytes. The percentage of antigen specific CD11a^hiCD8^ T cells that secrete IFN-γ, TNF-α or Granzyme B in response to peptide stimulation is shown.

*P < 0.05 and **P < 0.01. Data are representative of 2 experiments with at least 3–4 mice per group.

doi:10.1371/journal.pone.0041240.g003
ability to cause tumor regression/rejection in vivo thus far is unknown. Therefore, we next transferred splenocytes from Mam-A vaccinated HLA-A2+ transgenic mice into tumor-bearing SCID-beige mice and monitored tumor regression for 77 days (Fig. 4a–b). While all four of the Mam-A epitopes and full-length Mam-A initially induced successful tumor regression, tumors in mice receiving splenocytes from Mam-A2.2, Mam-A2.4 and Mam-A2.6 DNA vaccinated mice were capable of inducing longer-term tumor regression with Mam-A2.4 showing the greatest decrease in tumor volume, prolonged tumor remission and survival (Fig. 4b–c and Fig S2). Because all the Mam-A splenocytes induced some degree of tumor regression we explored the possibility that allore cognition was contributing to the tumor rejection. Therefore, we transfused naive splenocytes from non-immunized HLA-A2 transgenic mice into tumor-bearing SCID-beige mice and monitored tumor regression (Fig. 4a). Unlike the transfer of splenocytes from Mam-A vaccinated HLA-A2 transgenic mice, the transfer of splenocytes from naïve HLA-A2+ transgenic mice failed to induce tumor regression. Nonetheless, even if allore cognition is playing a role in the rejection process, tumors in mice receiving splenocytes from Mam-A vaccinated mice eventually grew back indicating that although CD8 T cells specific for Mam-A2 initially induce tumor regression in vivo, this vaccination regimen alone isn’t sufficient to prevent tumor re-growth.

The observation of tumor re-growth may indicate possible escape by the tumor cells through loss of tumor antigen. To determine if tumors retained their expression of Mam-A after they grew back, RNA was extracted from tumors isolated on day 37 from mice that received Mam-A2.4 specific splenocytes and the detection of Mam-A antigen was determined by PCR. Figure 4d demonstrates that tumors that grew back still expressed the Mam-A antigen. Additionally, we show that tumor cell lines derived from animals where tumors had previously grown back were equally capable of regressing as compared to the original Mam-A+ tumor cell line (Fig. 4e). Together these results indicate that loss of tumor antigen is not responsible for tumor outgrowth. Moreover, with the transfer of whole splenocytes antigen-specific CD8 T cells as well as regulatory T cells (CD4+CD25+ T cells) are introduced into the tumor-bearing host. However, when we depleted CD4 T cells prior to adoptive transfer of Mam-A2.4 specific splenocytes, the recipient SCID-beige mice did not show a further decrease in tumor burden (Fig S3), indicating that regulatory CD4 T cells are not responsible for tumor escape in our model.

CD8 T cells are not required for effector Mam-A2.4 specific CD8 T cells to enter the tumor site and cause tumor regression

As CD4 T cells are often shown to be essential for tumor rejection [25,26,27,28], we wanted to determine whether CD4 T cells control the recruitment of CD8 T cells indirectly through modifying the local tumor environment. Similar to CD8 T cells, immunohistochemical analysis showed that CD4 T cells infiltrated the spleen and DLN but in contrast to CD8 T cells there were no CD4 T cells detected in the tumor by day 7 (Fig. 5a–5b). However by day 28 post adoptive transfer, CD4 T cells had infiltrated the tumors (Fig. 5c–5d). Additionally, we analyzed tumors from mice that received spleen cells from Mam-A2.4 DNA vaccinated mice and found that CD4 T cells had infiltrated the tumor by day 21 and persisted at least until day 35 post spleenocyte transfer (Fig. 5e–5f). Morphometric analysis for CD4 T cells further confirmed these findings (Fig. 5f). These data reveal that early infiltration of CD4 T cells is not required for the initial recruitment of Mam-A specific CD8 T cells into the tumor. To further investigate the role of CD4 T cells in our model we wanted to determine if increasing the number of tumor-specific CD4 T cells would enhance tumor regression and or maintain the tumors in check for longer. Therefore, we utilized HLA-DR4+/hCD4+ mice, which recognize MHC class II antigens in the context of human HLA-DR1 and co-express human CD4. These HLA-DR4+/hCD4+ mice were vaccinated four times with DNA encoding for full-length Mam-A, which also encodes for the HLA-DR4 peptides. We then transferred spleen cells obtained from HLA-DR4+/hCD4+ mice (which contained ~2 x 10^4 Mam-A specific CD4 T cells, determined by intracellular IFN-γ staining, Fig S4) along with spleen cells from HLA-A2 transgenic mice vaccinated with Mam-A2.4 DNA into SCID-beige tumor bearing mice and examined tumor growth (Fig. 5g). The transfer of Mam-A specific CD4 T cells together with Mam-A specific CD8 T cells did not enhance tumor regression when compared to spleen cells from Mam-A2.4 DNA vaccinated mice alone (Fig. 5h). In addition enhanced tumor regression was not observed when CD4 T cells were depleted prior to adoptive transfer of spleen cells from Mam-A2.4 DNA vaccinated mice (Fig S3). Taken together these data indicate that while CD4 T cell help is not required for the recruitment of Mam-A specific CD8 T cells to the tumor site and additional help does not enhance the functional ability of the Mam-A specific CD8 T cells.

CD8 T cells from mice vaccinated with Mam-A2.4 DNA in combination with a single dose of total body irradiation leads to long-term tumor regression and prevents tumor re-growth

Studies have shown that TBI immediately before the transfer of splenocytes is known to reduce suppressive cells found within the tumor microenvironment as well as remove cytokine sinks and cause an increase in danger signals [11,12,13]. We therefore assessed whether combining a single low dose of TBI with Mam-A2.4 DNA vaccination could induce long-term tumor regression and prevent relapse. SCID-beige mice bearing large established tumors were treated with a single low dose of TBI (2.5 Gy) immediately prior to receiving splenocytes from Mam-A2.4 vaccinated HLA-A2+ transgenic mice. Tumor regression was compared to that seen in tumor-bearing SCID-beige who received Mam-A2.4-specific splenocytes without TBI (Fig. 6a). TBI in combination with adoptive transfer of Mam-A2.4 splenocytes not only enhanced the effects of DNA vaccination, evident by the continual regression seen up until day 67 after transfer, but more importantly, prevented tumor re-growth up to day 173 post splenic transfer at which time the animals were sacrificed (Fig. 6b–c). The effects of TBI alone in tumor-bearing mice was also analyzed and while initial tumor regression was observed, the tumors quickly began growing back almost reaching their original size by day 95, by which time animals from all control groups were severely ill and sacrificed. This reiterates the need for combination therapy, as it confirms that in addition to TBI therapy you also need to adoptively transfer tumor-specific CD8 T cells to induce an effective anti-tumor immune response that prevents tumor escape.

Total body irradiation reduces MSR1 and lipid uptake by tumor resident dendritic cells

In an effort to understand the mechanism by which TBI provides the necessary cues for the transferred Mam-A2.4 specific CD8 T cells to induce a productive anti-tumor response, we examined if low dose TBI has an effect on lipid uptake by resident tumor DCs using the lipophilic fluorescent dye BODIPY [29]. Analysis of lipid content from CD11c+/CD11b+ DCs isolated from
Figure 4. DNA vaccination with Mam-A2.4 induces tumor regression and prolongs survival in vivo. (A) HLA-A2 transgenic mice were vaccinated i.m a total of 4 times, separated by 2 week intervals, with 100 μg Mam-A full-length or epitope specific cDNA. Five days after the last vaccination 1 × 10⁶ Mam-A full-length or epitope specific spleen cells were harvested and injected i.p into SCID-beige mice bearing tumors that were approximately 4 mm². (B) Tumor regression and (C) survival was monitored in mice that received either splenocytes from non-vaccinated mice, tumor alone, full-length Mam-A, Mam-A2.1 or Mam-A2.2, Mam-A2.4 Mam-A2.6 specific spleen cells. Results representative of 4 independent experiments with n = 4 mice/group. (D) Mam-A expression was determined by PCR from the AU-565 tumor cell line either before transplant or 35 days after transplant following adoptive transfer of Mam-A2.4 splenic T cells. Lane 1 = molecular weight marker, lane 2 = blank, lane 3 = RNA from AU-565 tumor prior to transplant without reverse transcriptase (negative control), lane 4 = RNA from AU-565 tumor prior to transplant, lane 5 = RNA from AU-565 tumor 35 days after transplant without reverse transcriptase (negative control), lane 6 = RNA from AU-565 tumor 35 days post transplant. (E) Single cell suspensions were made from tumors excised from SCID-beige mice that received Mam-A2.4 specific splenocytes 35 days prior. Tumor cell suspensions were cultured for 7–10 days and then injected into SCID-beige mice. Once tumors were established (4 mm²), mice were reconstituted with splenocytes from Mam-A2.4 vaccinated HLA-A2 transgenic mice and tumor regression monitored. Control mice received the original tumor cell line. Data are representative of 3 experiments.

doi:10.1371/journal.pone.0041240.g004
Figure 5. CD4 T cells fail to infiltrate the tumor by day 7. SP, DLN and TIL sections from SCID-beige mice receiving splenocytes from HLA-A2\(^+\) transgenic mice vaccinated with cDNA encoding either full-length or Mam-A epitopes were analyzed by immunohistochemistry for the presence of CD4 T cells (A) 7 days and (C) 28 days post transfer (magnification of 20\(\times\)). Morphometric analysis was also performed (B) 7 and (D) 28 days post transfer and results are expressed as the mean (\(\pm SEM\)) of 3 different experiments. ND = none detected (E–F) SP, DLN and TIL tissue sections from tumor inoculated SCID-beige mice that received splenocytes from HLA-A2\(^+\) transgenic mice that received splenocytes from HLA-A2\(^+\) transgenic mice vaccinated with cDNA encoding Mam-A2.4 were

Adoptive Transfer and TBI Eradicates Breast Tumors
analyzed for the presence of CD4 T cells on days 7, 21, 28 and 35 post spleen cell transfer. (G–H) HLA-DR4+/hCD4+ transgenic mice and HLA-A2 transgenic mice were vaccinated i.m a total of 4 times, separated by 2 week intervals, with 100 μg Mam-A full-length or Mam-A2.4 specific cDNA (respectively). Five days after the last vaccination spleen cells were harvested from full-length cDNA vaccinated HLA-DR4+/hCD4+ transgenic mice and Mam-A2.4 cDNA vaccinated HLA-A2+ transgenic mice. 1×10^7 spleen cells from either Mam-A2.4 vaccinated mice, HLA-DR4+/hCD4+ vaccinated mice or 1×10^7 spleen cells from both Mam-A2.4 and HLA-DR4+/hCD4+ vaccinated were injected i.p into SCID-beige mice bearing human breast tumors derived from the AU-565 breast cancer cell line. Tumor-bearing SCID-beige mice without spleen cell transfer were used as controls. Tumor regression was monitored using calipers every four days (n = 4 mice/group). Data are representative of 2 experiments. *P<0.05, **P<0.01 and ***P<0.0001. doi:10.1371/journal.pone.0041240.g005

Figure 6. A single low dose of total body irradiation in combination with adoptive transfer of Mam-A2.4 CD8 T cells eliminates tumor and prevents relapse. (A) HLA-A2+ transgenic mice were vaccinated on days 0, 14, 28 and 42, with 100 μg Mam-A2.4 cDNA. Five days after the last vaccination, splenocytes were harvested and transferred i.p into tumor bearing SCID-beige mice immediately following the administration of 2.5 Gy TBI. (B) Tumor regression was monitored in SCID-beige mice that received either tumor only, 1×10^7 Mam-A2.4 specific spleen cells alone, TBI (2.5 Gy) only or 1×10^7 Mam-A2.4 specific spleen cells and TBI. Tumor regression was monitored using calipers every four days (n = 4 mice/group). (C) Survival curve of tumor-bearing mice. Day 0 indicates day of splenocyte transfer and TBI treatment. Data are representative of 3 independent experiments. **P<0.01. doi:10.1371/journal.pone.0041240.g006
and tumors of irradiated mice (2.5 Gy) showed a more than two-fold decrease in BODIPY staining on tumor resident DCs compared to DCs isolated from non irradiated tumor bearing mice (MFI 3196 and 8067, respectively). In contrast, we did not see any down-regulation of BODIPY from DCs isolated from either the spleen or tumor draining lymph nodes of irradiated mice, compared to non-irradiated hosts (data not shown). We next evaluated the level of expression of the macrophage scavenger receptor (Msr1), which has been shown to be upregulated in tumor resident DCs and responsible for the increased lipid uptake by DCs in tumor bearing hosts [29]. DCs isolated from tumors of mice that received low dose TBI had twofold less protein expression of Msr1 than control DCs isolated from tumors of non-irradiated mice (Fig. 7b). Additionally, low dose TBI did not increase the expression of the major histocompatibility complex (MHC) class II (Fig. 7c) or the co-stimulatory molecule CD80 on tumor resident DCs (Fig. 7d) or DCs located in the spleen or draining lymph nodes.

We next wanted to determine if Msr1 impacts the activation and proliferation of Mam-A2.4 specific CD8 T cells. For these experiments DCs were isolated from established tumors and incubated with Mam-A2.4 splenocytes, Mam-A2.4 specific peptide and tumor-explant supernatants along with 0, 10, 25 or 50 μg/ml of anti-Msr1. Control cultures received DCs from tumors that had been treated with 2.5 Gy and incubated with Mam-A2.4 splenocytes without anti-Msr1. Five days later the total number of CD8 T cells in cultures treated with anti-Msr1 was significantly greater than the total number of CD8 T cells in cultures that did not receive Msr1 antibody and comparable to cultures that received DCs from irradiated mice (Fig. 7e). In addition, cultures that were incubated with 10 μg of anti-Msr1 induced more CD8 T cells than cultures that received either 25 or 50 μg/ml of anti-Msr1 (Fig. 7e). Analysis of CD62L expression revealed that more CD8 T cells had been activated, evidenced by the down-regulation of CD62L, in the cultures that received non-irradiated DCs and anti-Msr1 compared to control wells that received no anti-Msr1 (11% and 40%, respectively) and comparable to cultures that received irradiated DCs (45%) (Fig. 7f). Interestingly, the total number of CD62L CD8 T cells was greater in cultures that received 10 μg/ml of Msr1 with non-irradiated DCs compared to cultures that received non-irradiated DCs (Fig. 7g). In contrast, the levels of IL-1β were significantly higher in the cultures that received the irradiated DCs compared to those cultures that received non-irradiated DCs and anti-Msr1 (Fig. 7h). To determine if blocking Msr1 directly affects lipid uptake we incubated tumor-derived DCs with tumor explants supernatants and anti-Msr1 for 4 hrs. This resulted in the down-regulation of Msr1 (Fig. 7i) and at least a four-fold decrease in BODIPY staining on the tumor-derived DCs that were incubated with anti-Msr1 compared to those tumor-derived DCs that did not receive the Msr1 antibody (MFI 2669 and 630, respectively) (Fig. 7j).

Discussion

While effector CD8 T cells are capable of exerting anti-tumor responses they often fail to control tumor growth long-term. Early adoptive transfer studies using effector T cells that were activated in vitro with either anti-CD3 mAb or tumor antigen and then expanded with large quantities of IL-2 [30,31] were found to have a terminal effector phenotype, characterized by a loss of CD62L and the expression of the senescence marker, KLRG1, as well as a decrease in proliferative capacity and IL-2 production [32,33]. Hence these T cells were found to have short-term anti-tumor capabilities. Based on these findings, it was then proposed that memory CD8 T cells could be a better alternative for improving adoptive immunotherapy due to their ability to survive, proliferate and traffic to the tumor site and respond more effectively. Memory T cells are often divided into two populations, known as TCM and TEM, although it remains controversial as to which memory CD8 T cell population provides the best anti-tumor immune response [32,34,35,36]. One study reported that the in vitro generation of TCM generated in the presence of IL-15 was far more effective at eradicating large, established tumors [34]. While others have reported that the presence of TEM in adoptively transferred CD8 T cells correlates with an anti-tumor immune response [32,35,36]. TCM are known to expand well in response to secondary activation and to survive long-term. Based on these qualities, TEM could be beneficial for preventing relapse and eradicating large tumors. TEM cells on the other hand preferentially locate to non-lymphoid tissue act as sentinel responders and have immediate cytotoxic activity [37]. This TEM population is more likely to act rapidly to halt the growth of existing tumors in peripheral tissue. More importantly, the location of the tumor is most likely going to dictate which memory CD8 T cell population will provide the most successful anti-tumor response.

Our results demonstrate that Mam-A specific CD8 T cells generated by DNA vaccination in vivo result in a heterogeneous CD8 T cell population consisting of both TCM and TEM like cells. Furthermore, upon transfer into tumor bearing mice Mam-A2 specific CD8 T cells which accumulate and survive longer predominantly become more like an effector memory T cell expressing low levels of both CD62L and CD27 while maintaining high levels of CD127. We also found that these Mam-A2 (Mam-A2.4) specific CD8 T cells secrete significantly more IFN-γ and TNF-α when stimulated ex vivo on both 7 and 28 days post transfer when compared to CD8 T cells specific for the other Mam-A epitopes or full length Mam-A. Furthermore, Mam-A2.4 specific CD8 T cells express more granyme B, localized to the tumor site in higher frequencies than CD8 T cells specific for the other Mam-A epitopes and resembled memory cell in that they expressed high levels of CD127 and CD122. Nonetheless, even with all these anti-tumor attributes the adoptive transfer of these Mam-A2.4 specific cells was not enough to prevent tumor recurrence.

Many tumor models also require help from CD4 T cells to achieve full tumor rejection [26,28] [38]. Our model showed a lack of CD4 T cell infiltration into the tumor at both early and late time points indicating the Mam-A specific CD8 T cells do not require further help to enter the tumor microenvironment and cause tumor regression. Additionally, enhanced tumor regression was not observed when we co-transfected splenocytes from Mam-A vaccinated DR4/hCD4 mice and Mam-A specific CD8 T cells from HLA-A2 transgenic mice. Together these data reveal that in our model, where CD4 T cells are present at the time of priming, CD8 T cells do not require additional signals from CD4 T cells to gain access to the tumor.

While we show that the Mam-A2.4 specific CD8 T cells secreted more IFN-γ, TNF-α and Granzyme B compared to either the full-length or the other epitope Mam-A specific CD8 T cells, this adoptive T cell therapy failed to prevent tumor relapse. While considerable effort has gone into developing cancer vaccines that induce a high frequency of memory CD8 T cells, little emphasis has been devoted to improving the functional qualities of the anti-tumor memory T cells. Thus to improve the functional attributes of the Mam-A2.4 CD8 T cells we treated SCID-beige mice bearing large established tumors with a single low dose of TBI [12] immediately prior to adoptive transfer of Mam-A specific CD8 T cells. The use of TBI is known to impact tumor growth and because of the undesirable side effects observed with higher doses...
Figure 7. Irradiation reduces Msr1 and lipid uptake by tumor resident DCs. (A) Lipid levels were measured in CD11c+CD11b+ tumor resident DCs isolated from either non-irradiated tumor bearing SCID-beige mice or tumor bearing SCID-beige mice that received TBI (2.5 Gy) 1 day prior. (B) Expression of Msr1 in tumor resident DCs from either non-irradiated or irradiated mice. (C) Expression of MHC class II and (D) CD80 on tumor resident DCs from either irradiated or non-irradiated mice. (E–H) 16103 CD11c+CD11b+ tumor resident DCs from non-irradiated tumor bearing SCID-beige mice were incubated with anti-Msr1 (10, 25 or 50 μg/ml) and cultured with 26104 Mam-A2.4 specific CD8 T cells, tumor-explant supernatants, and stimulated with Mam-A specific peptides. Control cultures received CD11c+CD11b+ tumor resident DCs from irradiated tumor bearing SCID-beige mice. (E) The total number of CD8 T cells after 5 days of culture with tumor explants supernatants. (F) CD62L expression on CD44hi CD8 T cells. (G) The total number of CD62Llo CD8 T cells in the cultures with tumor explants supernatants. (H) Culture supernatants were harvested and the levels...
Adoptive Transfer and TBI Eradicates Breast Tumors

In conclusion, we show that adoptive transfer of Mam-A specific CD8 T cells generated by DNA vaccination with all epitopes induces regression of established tumors but fails to maintain this anti-tumor response long term. However, when Mam-A specific CD8 T cells are combined with a single low dose of TBI this treatment induced not only regression of established tumors but more importantly prevented tumor recurrence. While TBI alone is able to induce regression of established tumors by impacting tumor growth directly. Secondly, this single low dose of TBI impacts the biology of tumor derived DCs by reducing both Msr1 expression and lipid uptake both of which have been shown to affect the ability of DCs to present tumor antigen. Thus when TBI is combined with the adoptive transfer of Mam-A specific CD8 T cells, TBI slows the growth of tumor cells directly and at the same time increases the ability of tumor derived DCs to present Mam-A specific tumor antigen to the adoptively transferred Mam-A specific CD8 T cells which results in the prevention of tumor recurrence. In summary, we propose that adoptive transfer of Mam-A specific CD8 T cells encompassing a heterogeneous memory phenotype including CD62L+/CD27high, CD62L+/CD27low and CD62Llow/CD27high together with low dose TBI, which effects both the rate of tumor growth and the ability of tumor derived DCs to present tumor antigens to tumor specific CD8 T cells, could be used as a therapy to effectively treat breast cancer patients.

Materials and Methods

Mice
C57BL/6 mice carrying the HLA-A*02:01 gene (HLA-A2+) were obtained from Jackson Laboratories. Severe combined immunodeficient (SCID) beige mice were purchased from Charles River Laboratories. C57BL/6 mice carrying the HLA-DRB1*0401 and human CD4 genes (HLA-DR4+) were generously provided by Dr G. Sondersrup via Dr. Tibor Glant (Department of Orthopedic Surgery, Rush University Medical Center). All protocols followed the guidelines approved by the Rush Institutional Animal Studies Committee.

Mam-A cDNA constructs
The full-length Mam-A cDNA was generously provided by Dr. Timothy P. Fleming (Department of Surgery, Washington University School of Medicine, St. Louis, MO). The Mam-A cDNA was cloned into the PCI-neo vector (Promega, Madison, WI). Four cDNA constructs containing the coding sequence for a Kozac site (CCAG) + a start codon (ATG) + the epitope cDNA sequences for the Mam-A2.1, Mam-A2.2, Mam-A2.4, or Mam-A2.6 epitopes + a stop codon (TAG) were cloned into the pcDNA3.1+ vector (Invitrogen, Carlsbad, CA) (See Table 1).

Mam-A Peptides and Mam-A cDNA vaccination
Mam-A-derived peptides that bind the HLA-A2 molecule (Mam-A2.1-Mam-A2.7) or HLA-DR4 (Mam-DR4.1, DR4.2, DR4.3, DR4.6, DR4.7 and DR4.8) were purchased from Sigma Aldrich (St. Louis, MO). Full-Length Mam-A cDNA was purified using an Endotoxin free plasmid purifying kit (Qiagen, Valencia, CA). HLA-A2+, or HLA-DR4+/hCD4+ transgenic mice were injected intramuscularly with 100 µg of Mam-A-derived cDNA (epitope or full-length). Mice were vaccinated 4 times at 2-week intervals. 5 days after the last vaccination, spleens and lymph nodes were harvested for transfer into tumor-bearing SCID-beige mice. Expression of Mam-A cDNA in the vaccinated HLA-A2+ transgenic mice was analyzed by PCR after the 3rd vaccination. The following primers were used: pcDNA3.1, 5’-GAGACC-
CAAGCTGGCTAGC-3', MamA2.1, 5'-ATCGCAGAGCGCTG-GAGTCG-3', LamA2.2, 5'-CGAGCATCGACCGATCA GC-3', MamA2.4, 5'-GTCTGTTCGAGCTGTTGAGG-3', MamA2.6, 5'-TGGAGTCTGAGATCGAGTCG-3'.

Breast Cancer cell lines

The human breast cancer cell line AU-565 (Mam-A+/HLA-A2*01) was purchased from the American Type Culture Collection (Manassas, VA) and cultured according to their instructions. The cell line was expanded and aliquots frozen down within the first week of receipt. Each experiment was performed using a fresh aliquot of AU-565 cells and checked for the expression of HLA-A2 by flow cytometry before use.

Spleen cell preparations

Single cell suspensions were prepared from lymph nodes and spleens as previously described [10]. Lymphocytes were isolated from tumors by digestion with 150 U/ml collagenase (Worthington Biochemical, Lakewood, NJ) in RPMI containing 1 mM MgCl₂, 1 mM CaCl₂, and 5% fetal bovine serum (FBS), at 37°C for 30 min. Cells were washed and resuspended in staining buffer (PBS with 2% FBS and 0.01% NaN₃).

Tumor regression model

SCID-beige mice were inoculated subcutaneously (s.c.) with AU-565 breast cancer cells (1×10⁶) resuspended in 300 μL of BD Matrigel basement membrane (BD Biosciences, Franklin Lakes, MD). Once the tumors reached ~4 mm² in diameter, SCID-beige mice were reconstituted i.p. with 1×10⁶ spleen cells from either epitope or full-length Mam-A cDNA vaccinated mice. Tumor growth was measured with calipers every four days.

Antibodies and flow cytometry

At the indicated times after tumor inoculation, lymphocytes were isolated and Mam-A-specific CD8 T cells were detected using tetramers to the Mam-A epitopes (Mam-A2.1–A2.6) provided by the NIH tetramer facility. For staining, lymphocytes were used to cultivate Mam-A-specific CD8 T cells from the spleens of Mam-A2.4 DNA vaccinated mice. Tumor regression was measured with calipers every four days.

In Vitro Msr1 blocking assay

Tumors from irradiated (2.5 Gy) or non-irradiated SCID-beige mice were harvested and CD11c⁺ DCs were purified by positive selection (Miltenyi, CA) (>85% CD11c⁺ by flow cytometry). CD11c⁺ T cells from the spleens of Mam-A2.4 DNA vaccinated mice were purified by positive selection (Miltenyi, CA) (>80% CD11c⁺ by flow cytometry) and then labeled with 5 μM CFSE at a concentration of 1 μL CFSE per 1×10⁶ cells/mL. The resulting

| Peptide   | AA position | AA Sequence | AA number |
|-----------|-------------|-------------|-----------|
| Mam-A2.1: | 83–92       | M-LYDSSLCDL | 10        |
| CACC-ATG-TTG ATC TAC GAC TCC AGC CTG GCC-CTC-TAG |
| Mam-A2.2: | 2–10        | M-KLLMVMLLA | 9         |
| CACC-ATG-AAG TTG CTG ATG CTG ATG GCC-TCC-TAG |
| Mam-A2.4: | 66–74       | M-FNQTDTEL  | 9         |
| CACC-ATG-TTC CTC AAC GAG ACA GAC GAG ACC CTG-TAG |
| Mam-A2.6: | 81–89       | MQLYDSSL    | 9         |
| CACC-ATG CAG CTG ATC TAC GAC TCC AGC CTC-TAG |

Kozac Site: CACC; Start Codon: ATG (not added in Mam-A2.6 as sequence begins with a Start Codon); Stop Codon: TAG
CFSE-labeled CD8+ T cells were then cultured (1 × 10^5/well) in a 96-well tissue plate (Becton Dickinson NJ) with tumor-explant supernatants in supplemented RPMI with CD11c+ DGs (1 × 10^4 cells/well) and stimulated with Mam-A2.4 peptide (Invitrogen, CA 40 μg/mL). Msrl blocking antibody was added to the corresponding wells at a concentration of 10, 25 or 50 μg/mL (Sera Tec NC). Cells were incubated at 37°C with 5% CO₂ for 5 days before being harvested and analyzed via flow cytometry.

Statistical analysis
Statistical significance was determined by Wilcoxon nonparametric tests. Differences in graft survival were assessed by means of 2-way log-rank (Mantel-Haenszel) test. Analyses were performed using the Prism 5.0 software (GraphPad, San Diego, CA) with significance set a-priori at P < 0.05.

Supporting Information

Figure S1 Vaccination with Mam-A2.2 and Mam-A2.4 epitope DNA induces a heterogeneous population of CD8 T cells. HLA-A2α transgenic mice were vaccinated four times with full-length Mam-A or Mam-A2.1, Mam-A2.2, Mam-A2.4 or Mam-A2.6 epitope cDNA. (A) The expression of CD122 and CD127 on splenic Mam-A tetramer positive CD8 T cells was determined five days after the last vaccination. (B) CD8 T cells were analyzed for IFN-γ production after stimulation with 40 μg/mL of the corresponding Mam-A peptides. The percentage of antigen specific CD8 T cells that secrete IFN-γ in response to peptide stimulation is shown. (C) Expression of Foxp3 on CD25+ CD4 T cells five days after the last vaccination is shown. Data are representative of 3 experiments with at least 2–3 mice per experiment. (TIF)

Figure S2 HLA-A2α transgenic mice were vaccinated i.m a total of 4 times. Five days after the last vaccination 1 × 10^7 Mam-A full-length or epitope specific spleen cells were harvested and injected i.p into tumor-bearing SCID-beige mice. Tumor regression was monitored in mice that received either splenocytes from unvaccinated mice, tumor alone, full-length Mam-A, Mam-A2.1 (left panel) or Mam-A2.2, Mam-A2.4 or Mam-A2.6 specific spleen cells (right panel). Tumor size was normalized and expressed as the percentage change from the initial tumor size. Results representative of 4 independent experiments with n = 4 mice/group. (TIF)

Figure S3 Depleting splenocytes of CD4 T cells prior to adoptive transfer does not enhance tumor regression. HLA-A2 transgenic mice were vaccinated i.m a total of 4 times, separated by 2-week intervals, with 100 μg Mam-A2.4 encoded cDNA. Five days after the last vaccination spleens were harvested and 1 × 10^7 whole splenocytes or splenocytes that had been CD4 T cell depleted by MACs column were injected i.p. into tumor bearing SCID-beige. Tumor regression was monitored in mice that received either: tumor alone, CD4-depleted Mam-A2.4 splenocytes, or Mam-A2.4 whole splenocytes (n = 4 mice/group). (TIF)

Acknowledgments
We thank Dr. T.P. Fleming (Washington University School of Medicine) for providing the Full-Length Mam-A cDNA; Dr. G. Sondersrud and Dr. T. Glant for providing the HLA-DR4/hCD4α transgenic mice; and C. Marchetti and S.H. Gandi for technical assistance; the Central Animal Facilities; the Rush Flow Cytometry Core Facility, which is supported in part by the James. B. Pendleton Charitable Trust, and Dr. Linda Baum for critical review of the paper.

Author Contributions
Conceived and designed the experiments: NML AJ ALM. Performed the experiments: NML MR. Analyzed the data: NML ALM. Wrote the paper: NML ALM.

References
1. Sallusto F, Lenig D, Forster R, Lipp M, Lanavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708–712.
2. Watson MA, Dintzis S, Darrose CM, Voss LE, DiPersio J, et al. (1999) Mammoglobin expression in primary, metastatic, and occult breast cancer. Cancer Res 59: 3029–3031.
3. Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, et al. (2004) Recognition of HLA-A2-restricted mammoglobin-Derived epitopes by CD8α cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 89: 29–41.
4. Narayanan K, Jaramillo A, Benshoff ND, Campbell LG, Fleming TP, et al. (2004) Response of established human breast tumors to vaccination with mammoglobin-A cDNA. J Natl Cancer Inst 96: 1380–1396.
5. Lacey SF, La Rosa C, Kaltcheva T, Srivastava T, Seidel A, et al. (2011) Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice. Blood 118: 2159–2169.
6. Gallicchio-Hawkins GV, Li X, Sanborn MG, Lumeli NA, Zaia JA. (2003) Use of Transgenic HLA A*02:01/Kb and HHD II mice to Evaluate Frequency of Cytomegalovirus IE1-Derived Peptide Usage in Eliciting Human CD8 Cytotoxic T lymphocytes Response. Journal of Virology 77: 4457–4462.
7. Shiraishi M, Arichi T, Nishioka M, Nomura T, Ikeda K, et al. (1995) CTL from unvaccinated mice, tumor alone, full-length Mam-A, Mam-A2.4 and epitope specific spleen cells (left panel) or Mam-A2.2, Mam-A2.4 or Mam-A2.6 specific spleen cells (right panel). Tumor size was normalized and expressed as the percentage change from the initial tumor size. Results representative of 4 independent experiments with n = 4 mice/group. (TIF)
8. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666–675.
9. Sussman JJ, Shu S, Sounduk VK, Chang AE (1994) Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol 1: 296–306.
10. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chiappa M, et al. (2007) Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TRAIL signaling. J Clin Invest 117: 2197–2206.
11. Gattinoni L, Finkelein SE, Klebanoff CA, Antony PA, Palmer DC, et al. (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202: 907–912.
12. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, et al. (2007) Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13: 5280–5299.
13. Masopust D, Veyss V, Marzo AL, Lefrancois L (2001) Preferential localization of tumor-specific CD8+ T cells. J Exp Med 202: 907–912.
14. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3: 666–675.
15. Sussman JJ, Shu S, Sounduk VK, Chang AE (1994) Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol 1: 296–306.
16. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Cassard L, et al. (2007) Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13: 5280–5299.
17. Masopust D, Veyss V, Marzo AL, Lefrancois L (2001) Preferential localization of effector memory cells in nonlymphoid tissue. Science 291: 2413–2417.
18. Weninger W, Crowley MA, Manjunath N, von Andrian UH (2001) Migratory properties of naive, effector, and memory CD8(+) T cells. J Exp Med 194: 953–966.
19. Marzo AL, Yagita H, Lefrancois L (2007) Cutting edge: migration to lymphoid tissues results in functional conversion of central to effector T cells. J Immunol 178: 36–40.
20. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northup JT, et al. (2005) Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6: 1236–1244.

21. Hand TW, Morre M, Kaech SM (2007) Expression of IL-7 receptor alpha is necessary but not sufficient for the formation of CD8+ T cells during viral infection. Proc Natl Acad Sci U S A 104: 11730–11735.

22. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Suth CD, et al. (2003) Selective expression of the interleukin 7 receptor identifies effector CD8+ T cells that give rise to long-lived memory cells. Nat Immunol 4: 1191–1198.

23. Schluns KS, Kieper WC, Jameson SC, LeFaucos I (2000) Interleukin-7 mediates the homeostasis of naive and memory CD8+ T cells in vivo. Nat Immunol 1: 426–432.

24. Bachmann MF, Wolint P, Schwarz K, Jager P, Ouenhaus A (2005) Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol 175: 4686–4696.

25. Thomas WD, Hersey P (1998) TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4+ T cell killing of target cells. J Immunol 161: 2195–2200.

26. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, et al. (2000) Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL-mediated antitumor immunity. J Immunol 165: 6047–6055.

27. Fallarino F, Grohmann U, Bianchi R, Vacc C, Fioretti MC, et al. (2000) Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo. J Immunol 165: 5495–5501.

28. Wong SB, Box R, Sherman LA (2008) Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180: 3122–3131.

29. Herber DL, Cao W, Nefedova Y, Novinsky SV, Nagaraj S, et al. (2010) Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 16: 880–886.

30. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, et al. (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 99: 16168–16173.

31. Powell DJ Jr., Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105: 241–250.

32. Szumanska JJ, Pavlik R, Winstead K, Finkelmann E (2004) Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion. Cancer Res 64: 9124–9130.

33. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616–1626.

34. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, et al. (2005) Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 102: 9571–9576.

35. Zhang P, Grote AL, de Vries VC, Uberwasser EJ, Turk MJ (2007) Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor. Cancer Res 67: 6468–6476.

36. Perret R, Rouches F (2008) Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo. Eur J Immunol 38: 2886–2895.

37. Sallusto F, Geginat J, Lanzavecchia A (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745–763.

38. Knudson KL, Distis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54: 721–728.